No Data
No Data
Heron Therapeutics Says Non-Opioid Pain Medication to Be Included in Proposed Medicare Programs
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.Zynrelef will be included under Medicare's Outpatient
Express News | Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And...
Express News | Heron Therapeutics Announces the Inclusion of Zynrelef® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the Opps and the Asc Payment System
Breakeven On The Horizon For Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Heron Therapeutics, Inc., a commercial-stage
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics Down Over 19%, On Pace for Largest Percent Decrease Since May 2023 -- Data Talk
Heron Therapeutics Inc.(HRTX) is currently at $2.79, down $0.68 or 19.62% --Would be lowest close since May 10, 2024, when it closed at $2.77 --On pace for largest percent decrease since May 12, 202
No Data